
SpineAI: Intelligent Platform for the Treatment and Monitoring of Idiopathic Scoliosis through the use of Artificial Intelligence
On Monday 6 November, the launch meeting of the SpineAI project was held. It took place at the IDONIAL technology centre facilities at the Gijón Science and Technology Park and brought together all the cooperating entities who will work on…

PRIM consolidates the pace of its revenue growth with an almost 9% increase in the first nine months of the year
The Company achieved an 11.2% increase in EBITDA, amounting to an accumulated €17.7 million in the third quarter.
The PRIM Group has strengthened its growth during the first nine months of the year, with an 8.8% increase in…

PRIM joins forces with the HM Hospitals Research Foundation to enhance the early detection of neurodegenerative diseases
Both institutions have agreed to conduct research in order to corroborate the usefulness of the ocular motility of the Oscann™ device for the early and progressive diagnosis of Alzheimer's and Parkinson's disease.
The research…

PRIM and AURA Innovative Robotics Join Forces to Revolutionise the Early Diagnosis of Neurological Diseases
According to data from the Spanish Society of Neurology (SEN), neurological diseases affect more than 7 million people in Spain. Their early diagnosis is essential to improve the prognosis and quality of life for patients and to provide…

PRIM BECOMES A SPONSOR OF THE IDIS FOUNDATION
The Board of Trustees of the Institute for the Development and Integration of Health (the IDIS Foundation) has approved the inclusion of PRIM as a new sponsor, resulting in it becoming one of the 23 entities that make up the IDIS Foundation…

PRIM IMPROVES REVENUES AND MARGINS AND ACHIEVES A 20% INCREASE IN NET PROFIT DURING THE FIRST HALF OF THE YEAR

PRIM holds its 2023 Ordinary General Shareholders’ Meeting where innovation and strategic alliances are the main protagonists
The medical technology company saw 17% growth in 2022, which is far beyond the 4% figure seen in the market as a whole
It reached €197 million in revenue last year, confirming the success of its 21/25 Strategic Plan
The PRIM Group…

PRIM announces that it is joining the United Nations Global Compact
We joined the UN Global Compact, as part of our 2023 ESG Master Plan to incorporate the universal framework of the Ten Principles and SDGs into our organisation's strategy.
Launched in the year 2000, the United Nations Global Compact…

PRIM strengthens its growth rate with a 17% improvement in consolidated revenues
The Board of Directors approves a second dividend of €0.11 per share being distributed for the 2022 financial year.
The Company has designed a comprehensive ESG Strategic Plan, with an outlook towards 2025 to advance with its implementation…
